IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria
This multicenter study aimed to explore whether baseline total immunoglobulin E (IgE) levels could predict omalizumab response in chronic spontaneous urticaria (CSU) patients. Refractory CSU patients, treated with omalizumab after failing second-generation H1-antihistamines, were analyzed retrospect...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Allergy |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/falgy.2024.1451296/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590889218736128 |
|---|---|
| author | Luis Felipe Ensina Larissa Brandão Luisa Karla Arruda Faradiba Sarquis Serpa Régis Albuquerque Campos Solange Rodrigues Oliveira Valle Paulo Ricardo Criado Sarbjit Singh Saini Roberta Fachini Jardim Criado |
| author_facet | Luis Felipe Ensina Larissa Brandão Luisa Karla Arruda Faradiba Sarquis Serpa Régis Albuquerque Campos Solange Rodrigues Oliveira Valle Paulo Ricardo Criado Sarbjit Singh Saini Roberta Fachini Jardim Criado |
| author_sort | Luis Felipe Ensina |
| collection | DOAJ |
| description | This multicenter study aimed to explore whether baseline total immunoglobulin E (IgE) levels could predict omalizumab response in chronic spontaneous urticaria (CSU) patients. Refractory CSU patients, treated with omalizumab after failing second-generation H1-antihistamines, were analyzed retrospectively across seven centers in Brazil. The study assessed total IgE levels at baseline, comparing responders to non-responders and considering complete and partial responses. The results showed a significant reduction in CSU symptoms post-treatment. Non-responders had lower baseline IgE levels. A sensitivity of 67.8% and specificity of 93.3% for predicting a response were found at an IgE level of 59.5 IU/ml. Similar values were observed for complete responders. Notably, a baseline IgE level lower than 59.5 IU/ml may indicate late responders. The study underscores the potential of baseline IgE levels as a predictive biomarker for omalizumab response in CSU patients. Further research, incorporating diverse populations and analyzing response variables, is warranted to validate these findings. |
| format | Article |
| id | doaj-art-7580473d114647698dbbf5bd3dd68be8 |
| institution | Kabale University |
| issn | 2673-6101 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Allergy |
| spelling | doaj-art-7580473d114647698dbbf5bd3dd68be82025-01-23T06:56:06ZengFrontiers Media S.A.Frontiers in Allergy2673-61012025-01-01510.3389/falgy.2024.14512961451296IgE as a predictor to omalizumab response in patients with chronic spontaneous urticariaLuis Felipe Ensina0Larissa Brandão1Luisa Karla Arruda2Faradiba Sarquis Serpa3Régis Albuquerque Campos4Solange Rodrigues Oliveira Valle5Paulo Ricardo Criado6Sarbjit Singh Saini7Roberta Fachini Jardim Criado8Department of Pediatrics, Federal University of São Paulo, São Paulo, BrazilDepartment of Pediatrics, Federal University of São Paulo, São Paulo, BrazilRibeirão Preto Medical School, University of São Paulo, Ribeirão Preto, BrazilDivision of Allergy and Immunology, Escola Superior de Ciências da Santa Casa de Misericordia de Vitória, Vitória, BrazilDepartment of Internal Medicine, Federal University of Bahia Medical School, Salvador, BrazilDepartment of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilDepartment of Dermatology, Centro Universitário Faculdade de Medicina do ABC, Santo André, BrazilDivision of Allergy and Clinical Immunology, The John Hopkins School of Medicine, Baltimore, MD, United StatesDepartment of Dermatology, Centro Universitário Faculdade de Medicina do ABC, Santo André, BrazilThis multicenter study aimed to explore whether baseline total immunoglobulin E (IgE) levels could predict omalizumab response in chronic spontaneous urticaria (CSU) patients. Refractory CSU patients, treated with omalizumab after failing second-generation H1-antihistamines, were analyzed retrospectively across seven centers in Brazil. The study assessed total IgE levels at baseline, comparing responders to non-responders and considering complete and partial responses. The results showed a significant reduction in CSU symptoms post-treatment. Non-responders had lower baseline IgE levels. A sensitivity of 67.8% and specificity of 93.3% for predicting a response were found at an IgE level of 59.5 IU/ml. Similar values were observed for complete responders. Notably, a baseline IgE level lower than 59.5 IU/ml may indicate late responders. The study underscores the potential of baseline IgE levels as a predictive biomarker for omalizumab response in CSU patients. Further research, incorporating diverse populations and analyzing response variables, is warranted to validate these findings.https://www.frontiersin.org/articles/10.3389/falgy.2024.1451296/fullurticariaimmunoglobulin Eomalizumabbiomarkerstreatment |
| spellingShingle | Luis Felipe Ensina Larissa Brandão Luisa Karla Arruda Faradiba Sarquis Serpa Régis Albuquerque Campos Solange Rodrigues Oliveira Valle Paulo Ricardo Criado Sarbjit Singh Saini Roberta Fachini Jardim Criado IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria Frontiers in Allergy urticaria immunoglobulin E omalizumab biomarkers treatment |
| title | IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria |
| title_full | IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria |
| title_fullStr | IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria |
| title_full_unstemmed | IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria |
| title_short | IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria |
| title_sort | ige as a predictor to omalizumab response in patients with chronic spontaneous urticaria |
| topic | urticaria immunoglobulin E omalizumab biomarkers treatment |
| url | https://www.frontiersin.org/articles/10.3389/falgy.2024.1451296/full |
| work_keys_str_mv | AT luisfelipeensina igeasapredictortoomalizumabresponseinpatientswithchronicspontaneousurticaria AT larissabrandao igeasapredictortoomalizumabresponseinpatientswithchronicspontaneousurticaria AT luisakarlaarruda igeasapredictortoomalizumabresponseinpatientswithchronicspontaneousurticaria AT faradibasarquisserpa igeasapredictortoomalizumabresponseinpatientswithchronicspontaneousurticaria AT regisalbuquerquecampos igeasapredictortoomalizumabresponseinpatientswithchronicspontaneousurticaria AT solangerodriguesoliveiravalle igeasapredictortoomalizumabresponseinpatientswithchronicspontaneousurticaria AT pauloricardocriado igeasapredictortoomalizumabresponseinpatientswithchronicspontaneousurticaria AT sarbjitsinghsaini igeasapredictortoomalizumabresponseinpatientswithchronicspontaneousurticaria AT robertafachinijardimcriado igeasapredictortoomalizumabresponseinpatientswithchronicspontaneousurticaria |